BTG (BTG) Share Price, News & Analysis

Company Overview

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 840 to 840
• 52-Week Range: N/A
• Volume: 271,742 shs
• Average Volume: 960,389 shs
• Market Capitalization: £3.26 billion
• P/E Ratio: 29.47
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTG Stock Analysis - Frequently Asked Questions

How were BTG's earnings last quarter?

BTG plc (LON:BTG) released its quarterly earnings results on Tuesday, May, 15th. The company reported $32.90 earnings per share for the quarter, topping the consensus estimate of $29.80 by $3.10.

How do I buy shares of BTG?

Shares of BTG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of BTG own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BTG investors own include Bodycote (BOY), Rapid7 (RPD), Editas Medicine (EDIT), Portola Pharmaceuticals (PTLA), Vectura Group (VEC), Bank of America (BAC) and B2Gold (BTO).

Company Calendar

• Last Earnings: 5/15/2018
• Today: 6/16/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Precious Metals
• Current Symbol: LON:BTG
• CIK: N/A
• Web: www.btgplc.com
• Phone: +44-20-75750000
• Fax: N/A
• Employees: 4,690
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 29.47
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.05
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: £914.10 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.25
• Book Value: GBX 355.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 388,256,992
• Free Float: N/A
• Market Cap: £3.26 billion
• Optionable: Not Optionable
• Beta: N/A